Baiya International Group Sets Record Date for 1-for-25 Reverse Stock Split

Written by Emily J. Thompson, Senior Investment Analyst

Source: SeekingAlpha

Updated: Dec 23 2025

0mins

BIYA+110.61%

Explore Agentic TradingLet AI Trade for You

Source: SeekingAlpha

Reverse Stock Split Announcement: Baiya International Group has approved a 1-for-25 reverse stock split of its class A ordinary shares, changing the par value from $0.0001 to $0.0025.
Effective Date: The reverse stock split will take effect on December 29, 2025, at 04:01 p.m. ET, with trading on a split-adjusted basis starting on December 30, 2025.
Reason for Split: The company is implementing the reverse stock split to meet Nasdaq's minimum bid requirement of $1.00 per ordinary share to maintain its listing.
Additional Information: The announcement includes references to financial information and ratings related to Baiya International Group.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy BIYA?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on BIYA

About BIYA

Baiya International Group Inc. is a holding company. The Company conducts all of its operations in China through Shenzhen Gongwuyuan Network Technology Co., Ltd. (Gongwuyuan) and its subsidiaries. Through Gongwuyuan, the Company builds a human resource (HR) technology company utilizing its cloud-based Internet platform to provide one-stop crowdsourcing recruitment and software as a service (SaaS)-enabled HR solutions in the employment marketplace (the Gongwuyuan Platform). Its business focuses on job matching services, entrusted recruitment services, project outsourcing services, and labor dispatching services. The Gongwuyuan Platform offers employment matching services. The Company contracts with domestic labor service companies to access the blue-collar labor to provide recruitment facilitation services to customers and employing companies. It connects its customers and employing companies with the available blue-collar labor from either the Company or the HR service companies.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Baiya International Launches 'Binance Plan'

2 days agoNewsfilter

Strategic Rebranding: Baiya International has rebranded its digital asset strategy to the 'Binance Plan' following a public vote that garnered approximately 89.2% support, marking a new direction in the company's long-term value creation and enhancing brand identity while optimizing capital allocation.
Capital Deployment: The company has fully deployed $1 million in dedicated funds for the acquisition of Binance Coin (BNB), establishing a strategic core position that signifies a shift from short-term market reactions to long-term asset allocation, thereby enhancing strategic scalability.
Dynamic Algorithm Strategies Activation: Baiya has concurrently activated four dynamic algorithmic strategies designed to maximize returns during market fluctuations, utilizing strategies A, B, C, and D to optimize trading costs and revenue generation.
Shareholder Value Repurchase Mechanism: The company plans to allocate 50% of the realized revenue during execution for potential share repurchases, aiming to align its digital asset strategy with broader long-term shareholder value objectives, thereby boosting investor confidence.

Baiya International Group FY 2025 Financial Report Analysis

Apr 30 2026seekingalpha

Revenue and Gross Profit Growth: Baiya International Group reported FY 2025 revenue of $16.5 million with a gross profit of $1.9 million, reflecting a 35.1% increase driven by improvements in project outsourcing, entrusted recruitment, and R&D technical services, indicating successful diversification of services.
Surge in Operating Expenses: Total operating expenses soared to $11.5 million in FY 2025, a staggering 754.6% increase primarily due to a $9.4 million rise in general and administrative expenses and an $800,000 increase in selling expenses, highlighting the company's aggressive investment in business expansion and market outreach.
Sales Expense Breakdown: Selling expenses reached $1 million in FY 2025, up 364.2%, with advertising and promotion costs increasing by $700,000, reflecting a strategic push to enhance brand visibility and market share through significant marketing expenditures.
R&D Expense Trends: Despite the overall rise in operating costs, R&D expenses decreased by $11,088, indicating a cautious approach to research investment that may impact future innovation capabilities and competitive positioning.

Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge

Mar 10 2026Benzinga

Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.

Rapt Therapeutics Acquired by GSK for $58 per Share, Valuing at $2.2 Billion

Jan 20 2026Benzinga

Acquisition Deal: GSK has agreed to acquire Rapt Therapeutics for $58 per share, representing an estimated total equity value of $2.2 billion, which will significantly enhance GSK's market position in the biopharmaceutical sector.
Stock Surge: Rapt Therapeutics' shares jumped 63.4% to $57.36 in pre-market trading, reflecting a positive market reaction to the acquisition, which may attract more investor interest in the company.
Market Impact: This acquisition not only increases shareholder value for Rapt but may also prompt other biotech firms to consider similar strategic acquisitions to enhance their competitiveness and market share.
Industry Outlook: With GSK's acquisition, Rapt's product development process is expected to accelerate, potentially leading to faster drug launches and further solidifying GSK's leadership position in the innovative pharmaceuticals market.

Baiya International Executes 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing

Dec 26 2025Globenewswire

Reverse Split Decision: Baiya International's board approved a 1-for-25 reverse stock split of its ordinary shares to meet Nasdaq's minimum $1.00 per share listing requirement, thereby ensuring the company's continued presence in the capital market.
Equity Adjustment Impact: Following the reverse split, the company's outstanding shares will decrease from approximately 29,644,605 to about 1,185,784, significantly reducing the number of shares in circulation and helping to elevate the share price to comply with exchange standards.
Exchange Notification: The reverse split will take effect at 4:01 PM on December 29, 2025, with ordinary shares beginning to trade on a split-adjusted basis on December 30, 2025, ensuring investors are promptly informed of the equity changes.
Shareholder Impact Explanation: All ordinary shareholders will be uniformly affected by the reverse split without needing to take any action, which protects shareholder interests and reflects the company's commitment to transparency with its investors.